About
AbbraTech develops a recombinant antibody discovery platform using its proprietary EPIVOLVEsm technology to identify and engineer antibodies against challenging disease targets, including those inaccessible by conventional methods.
Explore AbbraTech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.